# Regulatory T Cells for Amyotrophic Lateral Sclerosis

> **NCT05695521** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Cellenkos, Inc.** · enrollment: 66 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **BIOLOGICAL:** CK0803
- **OTHER:** Excipient

## Key facts

- **NCT ID:** NCT05695521
- **Lead sponsor:** Cellenkos, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-03
- **Primary completion:** 2026-05
- **Final completion:** 2027-12
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05695521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05695521, "Regulatory T Cells for Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05695521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*